Supernus Pharmaceuticals (LTS:0LB2) Common Stock : $0.1 Mil (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Supernus Pharmaceuticals Common Stock?

Supernus Pharmaceuticals's quarterly common stock stayed the same from Dec. 2023 ($0.1 Mil) to Mar. 2024 ($0.1 Mil) and stayed the same from Mar. 2024 ($0.1 Mil) to Jun. 2024 ($0.1 Mil).

Supernus Pharmaceuticals's annual common stock increased from Dec. 2021 ($0.1 Mil) to Dec. 2022 ($0.1 Mil) and increased from Dec. 2022 ($0.1 Mil) to Dec. 2023 ($0.1 Mil).

Supernus Pharmaceuticals Common Stock Historical Data

The historical data trend for Supernus Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals Common Stock Chart

Supernus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.05

0.06

Supernus Pharmaceuticals Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Common Stock	Get a 7-Day Free Trial															0.06	0.06	0.06	0.06	0.06

Supernus Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Supernus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (LTS:0LB2) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

SUPN:USA S49:Germany

Address

9715 Key West Avenue, Rockville, MD, USA, 20850

Website

https://www.supernus.com

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Supernus Pharmaceuticals Headlines

No Headlines